Expression of serum adiponectin, Lp-PLA2, IL-17 and correlation analysis with cognitive function in patients with Alzheimer's disease

doi:10.3877/cma.j.issn.2095-123X.2023.06.007

Abstract

Abstract:

Objective

To analyze the expression levels of serum adiponectin (APN), lipoprotein associated phospholipase A2 (Lp-PLA2), interleukin-17 (IL-17) and their relationship with cognitive function in patients with Alzheimer's disease (AD).

Methods

Eighty-two AD patients with income from May 2020 to May 2022 in Neurology Department of Taikang Tongji Hospital were selected as the observation group, and 45 healthy people who came to our hospital for physical examination in the same period were selected as the control group. The patients in AD group were divided into mild group, moderate group and severe group according to their condition with the clinical dementia assessment scale. The cognitive function of the patients was evaluated with the mini mental state scale (MMSE). The serum levels of APN, Lp-PLA2 and IL-17 of all the subjects were measured. The serum levels of APN, Lp-PLA2 and IL-17 in the observation group, the control group and the patients with different disease conditions were compared. The correlation between serum APN, Lp-PLA2, IL-17 and MMSE scores and the severity of the disease in AD patients were analysied.

Results

The serum APN level in the observation group was lower than that in the control group, and the levels of Lp-PLA2 and IL-17 were higher than that in the control group (P<0.05). The level of APN in the mild group was higher than that in the moderate group and higher than that in the severe group, the level of Lp-PLA2 and IL-17 in the mild group were lower than those in the moderate group and the severe group, the differences were statistically significant (P<0.05). The MMSE score of the control group was higher than that of the mild group, the moderate group and the severe group (P<0.05). MMSE score was positively correlated with APN, negatively correlated with Lp-PLA2 and IL-17 (P<0.05), and the severity of the disease was negatively correlated with APN, positively correlated with Lp-PLA2 and IL-17 (P<0.05). The area under the curve of serum APN, Lp-PLA2 and IL-17 alone or in combination to distinguish mild and moderate severe disease was 0.744, 0.862, 0.834 and 0.875.

Conclusion

There are abnormal expressions of APN, Lp-PLA2 and IL-17 in AD patients, which are closely related to cognitive function and have certain reference value for clinical differentiation of the severity of the disease.

Key words: Alzheimer's disease, Adiponectin, Lipoprotein-associated phospholipase A2, Interleukin 17, Cognitive function

Meng Zhang, Zhonghua Yu. Expression of serum adiponectin, Lp-PLA2, IL-17 and correlation analysis with cognitive function in patients with Alzheimer's disease[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2023, 13(06): 358-363.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2023.06.007

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2023/V13/I06/358

Figures/Tables 8

References 18

[1]	Salloway S, Chalkias S, Barkhof F, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies eevaluating aducanumab in patients with early Alzheimer disease[J]. JAMA Neurol, 2022, 79(1): 13-21. DOI: 10.1001/jamaneurol.2021.4161.
[2]	Ryder MI, Xenoudi P. Alzheimer disease and the periodontal patient: new insights, connections, and therapies[J]. Periodontol 2000, 2021, 87(1): 32-42. DOI: 10.1111/prd.12389.
[3]	Passeri E, Elkhoury K, Morsink M, et al. Alzheimer's disease: treatment strategies and their limitations[J]. Int J Mol Sci, 2022, 23(22): 13954. DOI: 10.3390/ijms232213954.
[4]	Oh M, Jang SY, Lee JY, et al. The lipoprotein-associated phospholipase A2 inhibitor Darapladib sensitises cancer cells to ferroptosis by remodelling lipid metabolism[J]. Nat Commun, 2023, 14(1): 5728. DOI: 10.1038/s41467-023-41462-9.
[5]	Douglas A, Stevens B, Lynch L. Interleukin-17 as a key player in neuroimmunometabolism[J]. Nat Metab, 2023, 5(7): 1088-1100. DOI: 10.1038/s42255-023-00846-3.
[6]	陈刚,曹雯炜,俞羚,等.最新AD研究用诊断标准: IWG-2标准[J].神经病学与神经康复学杂志, 2014, 11(3): 133-143.
[7]	万小勇,杨登元.蒙特利尔认知评估与MMSE量表在老年认知障碍筛查中的应用[J].成都医学院学报, 2012, 7(4): 648-650. DOI: 10.3969/j.issn.1674-2257.2012.04.047.
[8]	蒋小娟,吴越,刘晓伟,等.临床痴呆评定量表早期社区筛查阿尔茨海默病的效度[J].中华行为医学与脑科学杂志, 2021, 30(6): 554-559. DOI: 10.3760/cma.j.cn371468-20210401-00178.
[9]	Ossenkoppele R, van der Kant R, Hansson O. Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials[J]. Lancet Neurol, 2022, 21(8): 726-734. DOI: 10.1016/S1474-4422(22)00168-5.
[10]	Rostagno AA. Pathogenesis of Alzheimer's disease[J]. Int J Mol Sci, 2022, 24(1): 107. DOI: 10.3390/ijms24010107.
[11]	Jia J, Zhang Y, Shi Y, et al. A 19-year-old adolescent with probable Alzheimer's disease[J]. J Alzheimers Dis, 2023, 91(3): 915-922. DOI: 10.3233/JAD-221065.
[12]	Jucker M, Walker LC. Alzheimer's disease: from immunotherapy to immunoprevention[J]. Cell, 2023, 186(20): 4260-4270. DOI: 10.1016/j.cell.2023.08.021.
[13]	简晔,刘文锋,袁顺灵.脂联素在运动调节自噬并缓解阿尔茨海默病过程中的效应及机制[J].中国病理生理杂志, 2022, 38(1): 154-161. DOI: 10.3969/j.issn.1000-4718.2022.01.020.
[14]	王逸如,吴旭杰,林秀慧,等.血清尿酸、同型半胱氨酸、脂联素水平与阿尔茨海默病的关系研究[J].中国卫生检验杂志, 2021, 31(20): 2482-2485.
[15]	孙祝平,陈红英,陈思路.老年阿尔茨海默病患者血清Lp-PLA2, NLRP3水平表达及其与认知功能损害的相关性[J].现代检验医学杂志, 2020, 35(1): 49-52. DOI: 10.3969/j.issn.1671-7414.2020.01.013.
[16]	于艳红,王欣,张军,等.阿尔茨海默病患者血清P-tau-181、8-OHdG、Lp-PLA2水平与认知功能的关系及其预测价值分析[J].现代生物医学进展, 2021, 21(18): 3472-3476. DOI: 10.13241/j.cnki.pmb.2021.18.015.
[17]	尚晓峰,冉秀荣,李虹. miRNA-193b、Lp-PLA2、miR-146a与阿尔茨海默病严重程度的关系及预测疗效的价值[J].分子诊断与治疗杂志, 2020, 12(6): 813-817. DOI: 10.3969/j.issn.1674-6929.2020.06.029.
[18]	王洋洋,徐如祥.四面体框架核酸在颅脑损伤和阿尔兹海默病认知功能障碍中的治疗作用[J].中华神经创伤外科电子杂志, 2022, 8(6): 321-323. DOI: 10.3877/cma.j.issn.2095-9141.2022.06.001.

组别	例数	APN（μg/mL）	Lp-PLA2（μg/L）	IL-17（ng/L）
观察组	82	4.96±1.70	52.30±13.10	128.76（99.34，158.43）
对照组	45	7.43±2.01	22.61±4.85	15.25（12.07，18.09）
t/Z值		7.351	-14.638	-9.295
P值		<0.001	<0.001	<0.001

组别	例数	APN（μg/mL）	Lp-PLA2（μg/L）	IL-17（ng/L）
观察组	82	4.96±1.70	52.30±13.10	128.76（99.34，158.43）
对照组	45	7.43±2.01	22.61±4.85	15.25（12.07，18.09）
t/Z值		7.351	-14.638	-9.295
P值		<0.001	<0.001	<0.001

组别	例数	APN（μg/mL）	Lp-PLA2（μg/L）	IL-17（ng/L）
轻度组	21	6.10±1.85	39.65±10.31	94.78（66.97，116.52）
中度组	30	5.11±1.50^a	51.13±8.46^a	139.75（118.19，193.99）^a
重度组	31	4.03±1.23^ab	62.01±10.62^ab	155.25（128.33，230.30）^ab
F/χ²值		12.080	32.935	31.938
P值		<0.001	<0.001	<0.001

组别	例数	APN（μg/mL）	Lp-PLA2（μg/L）	IL-17（ng/L）
轻度组	21	6.10±1.85	39.65±10.31	94.78（66.97，116.52）
中度组	30	5.11±1.50^a	51.13±8.46^a	139.75（118.19，193.99）^a
重度组	31	4.03±1.23^ab	62.01±10.62^ab	155.25（128.33，230.30）^ab
F/χ²值		12.080	32.935	31.938
P值		<0.001	<0.001	<0.001

控制变量	指标	MMSE评分		病情严重程度
控制变量	指标	r值	P值	r值	P值
无	APN	0.827	<0.001	-0.469	<0.001
	Lp-PLA2	-0.925	<0.001	0.669	<0.001
	IL-17	-0.871	<0.001	0.628	<0.001
年龄、性别、教育程度	APN	0.834	<0.001	-0.515	<0.001
	Lp-PLA2	-0.926	<0.001	0.690	<0.001
	IL-17	-0.883	<0.001	0.673	<0.001

Please choose a citation manager

Content to export